Peng Ziyi, Kalim Muhammad, Lu Yong
Houston Methodist Cancer Center/Weill Cornell Medicine, Houston, TX 77030, USA.
Cancer Biol Med. 2025 Jan 17;21(12):1104-19. doi: 10.20892/j.issn.2095-3941.2024.0390.
Oncolytic virotherapy (OVT) is a promising option for cancer treatment. OVT involves selective oncolytic virus (OV) replication within cancer cells, which triggers anti-tumor responses and immunostimulation. Despite promising potential, OVT faces critical challenges, including insufficient tumor-specific targeting, which results in limited tumor penetration and variability in therapeutic efficacy. These challenges are particularly pronounced in solid tumors with complex microenvironments and heterogeneous vascularization. A comprehensive research program is currently underway to develop and refine innovative delivery methods to address these issues to enhance OVT precision and efficacy. A principal area of investigation is the utilization of cellular carriers to enhance the delivery and distribution of OVs within tumor microenvironments, thereby optimizing immune system activation and maximizing anti-tumor effects. This review offers a comprehensive overview of the current strategies that are being used to enhance the delivery of OVs via cellular carriers with the goal of improving the clinical impact of OVT in cancer therapy.
溶瘤病毒疗法（OVT）是一种很有前景的癌症治疗选择。OVT涉及溶瘤病毒（OV）在癌细胞内的选择性复制，这会引发抗肿瘤反应和免疫刺激。尽管有潜在的前景，但OVT面临着关键挑战，包括肿瘤特异性靶向不足，这导致肿瘤渗透受限和治疗效果的变异性。这些挑战在具有复杂微环境和异质性血管生成的实体瘤中尤为明显。目前正在开展一项全面的研究计划，以开发和完善创新的递送方法来解决这些问题，从而提高OVT的精准度和疗效。一个主要的研究领域是利用细胞载体来增强OV在肿瘤微环境中的递送和分布，从而优化免疫系统激活并最大化抗肿瘤效果。这篇综述全面概述了目前通过细胞载体增强OV递送的策略，目的是提高OVT在癌症治疗中的临床影响。
